Biocon Limited is a biopharmaceutical company. The Company focuses to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer. Through its products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. The Company has developed and taken a range of Novel Biologics, Biosimilars, differentiated Small Molecules and affordable Recombinant Human Insulin and Analogs from Lab to Market. The Company's brands include INSUGEN (rh-insulin), BASALOG (Glargine), CANMAb (Trastuzumab), BIOMAb-EGFR (Nimotuzumab) and ALZUMAb (Itolizumab), an anti-CD6 monoclonal antibody. It has a pipeline of Biosimilars and Novel Biologics at various stages of development, including Insulin Tregopil, an oral insulin analog.

Pharmaceutical

Biocon

Siddharth Mittal

Indranil M.

Lance Giordano

Manali Bhide

Saravanan Krishnan

Satyanarayana Turlapati

Thiruvazhi Marban

Baskaran Karunanithi

Christiane Hamacher

The Leadership Team at Biocon is responsible for steering the company towards achieving its mission of reducing therapy costs for chronic diseases. This team sets strategic directions, oversees major operational decisions, and coordinates efforts across various departments to ensure the successful development and commercialization of Biocon's novel biologics, biosimilars, and affordable therapeutic products. The Leadership Team is instrumental in fostering innovation, maintaining regulatory compliance, and driving global market expansion.

Leadership Team

Leadership Team

About

Team members